KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBITDA (2016 - 2025)

Nektar Therapeutics has reported EBITDA over the past 16 years, most recently at -$27.7 million for Q4 2025.

  • Quarterly results put EBITDA at -$27.7 million for Q4 2025, down 292.81% from a year ago — trailing twelve months through Dec 2025 was -$140.1 million (down 33.18% YoY), and the annual figure for FY2025 was -$140.1 million, down 33.18%.
  • EBITDA for Q4 2025 was -$27.7 million at Nektar Therapeutics, up from -$31.7 million in the prior quarter.
  • Over the last five years, EBITDA for NKTR hit a ceiling of $14.3 million in Q4 2024 and a floor of -$152.8 million in Q2 2022.
  • Median EBITDA over the past 5 years was -$50.2 million (2023), compared with a mean of -$66.6 million.
  • Biggest five-year swings in EBITDA: soared 142.82% in 2024 and later plummeted 292.81% in 2025.
  • Nektar Therapeutics' EBITDA stood at -$112.9 million in 2021, then skyrocketed by 53.53% to -$52.5 million in 2022, then surged by 36.13% to -$33.5 million in 2023, then soared by 142.82% to $14.3 million in 2024, then plummeted by 292.81% to -$27.7 million in 2025.
  • The last three reported values for EBITDA were -$27.7 million (Q4 2025), -$31.7 million (Q3 2025), and -$36.2 million (Q2 2025) per Business Quant data.